Netherton Syndrome is a rare and severe genetic disorder characterized by chronic skin inflammation and scaling. QRX003 contains a broad-spectrum serine protease inhibitor targeting kallikreins ...

Targeting kallikreins, which are thought to lead to the clinical manifestations of Netherton Syndrome, could be an ideal approach.” Quoin CEO, Dr. Michael Myers, added, “Following our recent ...

Quoin Pharmaceuticals (QNRX) announces interim clinical data from two of its ongoing Netherton Syndrome clinical studies. Data from the first subject being dosed twice-daily in Quoin’s ongoing ...

Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX), a specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has given the green light to commence an additional ...

today announces positive interim clinical data from two of its ongoing Netherton Syndrome clinical studies. Data from the first subject being dosed twice-daily in Quoin’s ongoing open label ...

(QNRX), a clinical-stage specialty pharmaceutical company, on Wednesday, announced positive interim data from two ongoing clinical trials for topical lotion, QRX003, for Netherton Syndrome.

18, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today ...

We remain steadfast in our commitment to develop a safe and effective treatment for the Netherton Syndrome community.” About Quoin Pharmaceuticals Ltd. Quoin Pharmaceuticals Ltd. is a clinical ...